# A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

> **NCT04131309** · PHASE2 · COMPLETED · sponsor: **Stichting European Myeloma Network** · enrollment: 40 (actual)

## Conditions studied

- Light Chain (AL) Amyloidosis, Stage 3B

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Bortezomib Injection
- **DRUG:** Dexamethasone oral tablet

## Key facts

- **NCT ID:** NCT04131309
- **Lead sponsor:** Stichting European Myeloma Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-23
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-01-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04131309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04131309, "A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04131309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*